Company / Cash & Equivalents
Teladoc Health, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$781.1M
FY2025
5-year range
$781.1M / $1.3B
FY2021-FY2025
Trend
-39.8%
vs FY2024
Sector context
#36 of 152
Health Care
What the data says
Teladoc Health, Inc.'s cash & equivalents of $781M is higher than 76% of companies in the Health Care sector (FY2025). Declined from $1.1B to $781M over the past 2 years.
Based on SEC 10-K filings.
$781M in FY2025 with a 5-year CAGR of +1.3%. Top quartile in the Health Care sector.
Declined from $1.1B to $781M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.2%
- 5-Year CAGR
- +1.3%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 152This company $781.1M Sector average $1.2B
▼
-33.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 39.8% year-over-year.
- Ranks #36 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $781.1M | -39.8% |
| FY2024 | $1.3B | +15.5% |
| FY2023 | $1.1B | +22.4% |
| FY2022 | $918.2M | +2.8% |
| FY2021 | $893.5M | +21.8% |
| FY2020 | $733.3M | +42.6% |
| FY2019 | $514.4M | +21.3% |
| FY2018 | $424.0M | +890.2% |
| FY2017 | $42.8M | -14.4% |
| FY2016 | $50.0M | -9.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026